


RECEIVED  
CENTRAL FAX CENTER

AUG 21 2006

Amendment to the Claims:

1. (currently amended) A piperazinyl pyrimidinyl nitroso compound of the formula (II)



where (P)-R\_N is:

-N=O,

(P)-R\_{N-1}-O-OC-(CH\_2)\_n-, where n\_1 is 1 thru through 6 and where (P)-R\_{N-1} is H- or C\_1-C\_4 alkyl,

or C\_1-C\_6 alkyl[[,]] :

where (P)-R\_{2-1} is:

-N=O and or

C\_1-C\_6 alkyl;

where (P)-R\_{2-2} is:

C\_1-C\_6 alkyl; and or

where (P)-R\_{2-1} and (P)-R\_{2-2} are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;

where (P)-R\_{4-1} is

-N=O and or

C\_1-C\_6 alkyl; and

where (P)-R<sub>4-2</sub> is


C<sub>1</sub>-C<sub>6</sub> alkyl; and or

where (P)-R<sub>4-1</sub> and (P)-R<sub>4-2</sub> are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl; and or a pharmaceutically acceptable salt thereof.

2. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where the variable substituents (P)-R<sub>2-1</sub> and (P)-R<sub>2-2</sub> are the same as the variable substituents (P)-R<sub>4-1</sub> and (P)-R<sub>4-2</sub>.
3. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R<sub>2-1</sub> and (P)-R<sub>2-2</sub>, and (P)-R<sub>4-1</sub> and (P)-R<sub>4-2</sub> are both taken together with the attached nitrogen atom to form pyrrolidinyl.
4. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 which contains 3 -N=O groups.
5. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 which contains 4 -N=O groups.
6. (currently amended) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids: acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, biartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycolylarsanilic, hexamic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsuffuric, mucic, muconoic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric,

monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalacturonic, propionic, salicyclic, stearic, succinic, succinic, sulfamic, sulfanilic, sulfonic, tannic, tartaric, teoclic, and toluenesulfonic.

7. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R<sub>N</sub> is -N=O.
8. (currently amended) A piperazinyl pyrimidinyl nitroso compound according to claim 7 where the substituted pyrimidinyl nitroso compound is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-(4-nitroso-1-piperazinyl)pyrimidine.
9. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 1 where (P)-R<sub>N</sub> is (P)-R<sub>N-1</sub>-O-OC-(CH<sub>2</sub>)<sub>n1</sub>-.
10. (original) A piperazinyl pyrimidinyl nitroso compound according to claim 9 where the piperazinyl pyrimidinyl nitroso compound is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-[4-(3-propionic acid methyl ester)piperazin-1-yl]pyrimidine.
11. (canceled)
12. (canceled)
13. (currently amended) A method of treating ischemic injury in a human who has an ischemic disease selected from the group consisting of coronary heart disease, stroke, hemorrhagic shock, peripheral vascular disease (upper and lower extremities) and transplant related injuries and who is in need of treatment which comprises in need thereof comprising administering to that the human an anti-ischemic effective amount of a piperazinyl pyrimidinyl nitroso compound of formula (II)



where (P)-R<sub>N</sub> is:

-N=O,

(P)-R<sub>N-1</sub>-O-OC-(CH<sub>2</sub>)<sub>n1</sub>- where n<sub>1</sub> is 1 thru through 6 and where (P)-R<sub>N-1</sub> is H- or C<sub>1</sub>-C<sub>4</sub> alkyl,

or C<sub>1</sub>-C<sub>6</sub> alkyl[[,]] :

where (P)-R<sub>2-1</sub> is:

-N=O and or

C<sub>1</sub>-C<sub>6</sub> alkyl;

where (P)-R<sub>2-2</sub> is:

C<sub>1</sub>-C<sub>6</sub> alkyl; and or

where (P)-R<sub>2-1</sub> and (P)-R<sub>2-2</sub> are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;

where (P)-R<sub>4-1</sub> is


-N=O and or

C<sub>1</sub>-C<sub>6</sub> alkyl; and

where (P)-R<sub>4-2</sub> is

C<sub>1</sub>-C<sub>6</sub> alkyl; and or

where (P)-R<sub>2-1</sub> and (P)-R<sub>2-2</sub> are taken together with the attached nitrogen atom to form a ring selected from the group consisting of: pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and 4-nitroso-1-piperazinyl;



and/or a pharmaceutically acceptable salt thereof.

14. (currently amended) A method of ~~treating a human who has an ischemic disease according to claim 13 where the administering is IV or oral compound is administered intravenously or orally.~~
15. (currently amended) A method of ~~treating a human who has an ischemic disease according to claim 13 where the IV anti-ischemic compound is administered intravenously and the effective amount is from about 5 to about 100 mg/kg/dose.~~
16. (currently amended) A method of ~~treating a human who has an ischemic disease according to claim 13 where the oral anti-ischemic compound is administered orally and the effective amount is from about 5 to about 50 mg/kg/dose.~~
17. (canceled)
18. (currently amended) A method of ~~treating a human who has an ischemic disease according to claim 17 where the piperazinyl pyrimidinyl nitroso compound (II) is 5-nitroso-2,4-di(1-pyrrolidinyl)-6-(4-nitroso-1-piperazinyl)pyrimidine or 5-~~

**nitroso-2,4-di(1-pyrrolidinyl)-6-[4-(3-propionic acid methyl ester)piperazin-1-yl]pyrimidine.**